DermTech, Inc. (DMTK)
| Market Cap | 203.60M |
| Revenue (ttm) | 13.03M |
| Net Income (ttm) | -93.38M |
| Shares Out | 29.94M |
| EPS (ttm) | -2.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 506,104 |
| Open | 7.03 |
| Previous Close | 7.30 |
| Day's Range | 6.62 - 7.10 |
| 52-Week Range | 6.39 - 48.32 |
| Beta | 0.94 |
| Analysts | Buy |
| Price Target | 33.49 (+392.5%) |
| Earnings Date | May 3, 2022 |
About DMTK
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 i...
Financial Performance
In 2021, DermTech's revenue was $11.84 million, an increase of 101.16% compared to the previous year's $5.89 million. Losses were -$78.34 million, 114.8% more than in 2020.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for DMTK stock is "Buy." The 12-month stock price forecast is 33.49, which is an increase of 392.50% from the latest price.
News
DermTech Reinforces Longstanding Mission to Help Reduce Melanoma Deaths, Aligning with the Biden Administration's Ren...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its co...
DermTech Kicks Off Second Annual #Stickit2Melanoma Campaign, Raising Awareness for Melanoma and the Importance of Ski...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the re...
DermTech, Inc. (DMTK) Reports Q1 Loss, Misses Revenue Estimates
DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -18.82% and 1.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
DermTech Reports First-Quarter 2022 Financial Results; Company Affirms Full-Year 2022 Outlook
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported its fir...
DermTech Announces Publication of New GvHD Clinical Research Conducted in Collaboration with Memorial Sloan Kettering...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the pu...
DermTech Expands Telehealth Application, DermTech Connect, Across 44 States
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the ex...
DermTech to Showcase DermTech Stratum, an Expanded Translational Medicine Service Offering, at San Diego's Inaugural ...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that i...
DermTech Announces Release Date for First-Quarter 2022 Financial Results
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, will host a conference...
CasperLabs Appoints Michael Dobak as Company's First Chief Marketing Officer to Drive Business Adoption of Blockchain...
ZUG, Switzerland & NEW YORK--(BUSINESS WIRE)--CasperLabs, a leading blockchain software company for the enterprise market, is pleased to announce that Michael Dobak has been appointed to the position of...
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the grant to one new em...
DermTech Study, “Cost-Benefit Analysis of the Pigmented Lesion Assay When Introduced into the Visual Assessment / His...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that S...
DermTech, Inc. (DMTK) Reports Q4 Loss, Lags Revenue Estimates
DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -20.55% and 5.97%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
DermTech Reports Fourth Quarter and Full Year 2021 Financial Results
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported financial results as of ...
DermTech Management to Present at Upcoming Investor Conferences
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that its management wil...
DermTech Welcomes Adelle Walker as Vice President of Consumer Products
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the ad...
DermTech to Announce Fourth Quarter and Full-Year Financial Results
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that it plans to releas...
DermTech Management to Participate in Upcoming Investor Conferences
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that its management wil...
Should You Sell DermTech and GoodRx Stocks Right Now?
It may depend on the underlying premise of what the company is all about.
Want $1 Million? Buy and Hold These 2 Stocks for the Next Decade
These two stocks could provide life-changing returns in 10 years.
BioIQ and DermTech Enter into an Agreement to Add Non-invasive DermTech Melanoma Test to BioIQ's Health Testing Solut...
ATLANTA and LA JOLLA, Calif., Dec. 15, 2021 /PRNewswire/ -- BioIQ, Inc., ("BioIQ") an analytics-driven population health and testing platform company for top employers, health plans, and government agen...
Why DermTech Still Has Ten-Bagger Potential
Skin-cancer detection could lead to big returns for this stock.
DermTech Unveils DermTech Stratum, an Expanded Translational Medicine Service Offering for Non-invasive Biomarker Ana...
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the ex...
This Is the Main Problem With DermTech's Q3 Results
Nothing major changed for the skin genomics company in Q3.
DermTech Presents Precision Approaches to Personalized Dermatology at 2021 Dermatology Drug Development Summit
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its session presentatio...
Got $50? 3 Roughed-Up Growth Stocks Set to Soar
These stocks have grown quarterly sales 34%, 43%, and 140% year over year.